Dimerix (ASX:DXB), the Australian biopharmaceutical company developing therapies for kidney disease, confirmed that BioMarin Pharmaceutical (NASDAQ:BMRN) has entered into a definitive agreement to acquire its US commercial licensing partner, Amicus Therapeutics (NASDAQ:FOLD), in an all-cash transaction valued at approximately US$4.8 billion.
Under the terms of the agreement, BioMarin’s acquisition will include the Dimerix commercial licensing contract with Amicus, encompassing all associated rights and obligations.
The existing licensing agreement will remain in full force until the transaction closes, with Amicus and Dimerix continuing to collaborate on the US development and commercialisation of DMX-200.
The licensing arrangement between Dimerix and Amicus makes Dimerix eligible to receive up to US$590 million in upfront, development, and sales milestone payments, in addition to tiered royalties on net US sales.
Payments already received include US$30 million upon execution of the agreement in May 2025, with further milestones tied to development, first sales, future indications, and overall sales performance.
Dimerix's licensing agreements in territories outside the US remain unaffected, including partnerships with Advanz Pharma, Taiba, and Fuso.
Collectively, these deals could provide up to ~$1.4 billion in upfront and milestone payments, alongside royalties, with over $65 million received to date.
At the time of reporting, Dimerix's share price was $0.60.